| Mark Murphy, MD | |
|
1400 S Dobson Rd, Mesa, AZ 85202-4707 | |
| (480) 835-3000 | |
| Not Available |
| Full Name | Mark Murphy |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 39 Years |
| Location | 1400 S Dobson Rd, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033103601 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 16272 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner - University Medical Center Phoenix | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Canyon State Anesthesiologists Pc | 8628069986 | 9 |
News Archive
The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation,the largest meeting of ear, nose, and throat doctors in the world, will convene September 26-29, in Boston, MA. The official abstract supplement for the annual meeting is now available with the regular August 2010 issue of Otolaryngology - Head and Neck Surgery.
In Virginia, Democratic lawmakers are pushing a proposal to establish a state-based exchange. These legislators see their plan, which is built on the argument that state action would keep the federal government from being involved, will draw support from others regardless of their feelings about the health law itself. Meanwhile, Montana's high-risk insurance pool is running out of cash.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that the Welsh Ambulance Services NHS is equipping its frontline ambulances with the ZOLL E Series EMS monitor/defibrillator.
› Verified 8 days ago
| Entity Name | Canyon State Anesthesiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265439525 PECOS PAC ID: 8628069986 Enrollment ID: O20040524001249 |
News Archive
The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation,the largest meeting of ear, nose, and throat doctors in the world, will convene September 26-29, in Boston, MA. The official abstract supplement for the annual meeting is now available with the regular August 2010 issue of Otolaryngology - Head and Neck Surgery.
In Virginia, Democratic lawmakers are pushing a proposal to establish a state-based exchange. These legislators see their plan, which is built on the argument that state action would keep the federal government from being involved, will draw support from others regardless of their feelings about the health law itself. Meanwhile, Montana's high-risk insurance pool is running out of cash.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that the Welsh Ambulance Services NHS is equipping its frontline ambulances with the ZOLL E Series EMS monitor/defibrillator.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Murphy, MD Po Box 29211, Phoenix, AZ 85038-9211 Ph: (602) 273-6770 | Mark Murphy, MD 1400 S Dobson Rd, Mesa, AZ 85202-4707 Ph: (480) 835-3000 |
News Archive
The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation,the largest meeting of ear, nose, and throat doctors in the world, will convene September 26-29, in Boston, MA. The official abstract supplement for the annual meeting is now available with the regular August 2010 issue of Otolaryngology - Head and Neck Surgery.
In Virginia, Democratic lawmakers are pushing a proposal to establish a state-based exchange. These legislators see their plan, which is built on the argument that state action would keep the federal government from being involved, will draw support from others regardless of their feelings about the health law itself. Meanwhile, Montana's high-risk insurance pool is running out of cash.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.
ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that the Welsh Ambulance Services NHS is equipping its frontline ambulances with the ZOLL E Series EMS monitor/defibrillator.
› Verified 8 days ago
Dr. John G Meernik, M D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6247 E. Main Street, Suite 8, Mesa, AZ 85205 Phone: 480-981-9151 Fax: 480-981-0527 | |
Dr. Mikulkumar D Shah, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6644 E Baywood Ave, Mesa, AZ 85206 Phone: 480-321-2000 | |
Timothy E Black, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1500 S Dobson Road, Suite 203, Mesa, AZ 85202 Phone: 480-844-7100 Fax: 480-512-5486 | |
Joseph M Levine, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1500 S Dobson Rd, Ste 203, Mesa, AZ 85202 Phone: 480-844-7100 Fax: 480-512-5486 | |
Robert Thomas, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-272-8411 Fax: 480-361-1435 | |
Todd G Peterson, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6247 E. Main Street, Suite 8, Mesa, AZ 85205 Phone: 480-981-9151 Fax: 480-981-0527 |